MA43251A - Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 - Google Patents

Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2

Info

Publication number
MA43251A
MA43251A MA043251A MA43251A MA43251A MA 43251 A MA43251 A MA 43251A MA 043251 A MA043251 A MA 043251A MA 43251 A MA43251 A MA 43251A MA 43251 A MA43251 A MA 43251A
Authority
MA
Morocco
Prior art keywords
receptor modulators
indole derivatives
substituted indole
pge2 receptor
pge2
Prior art date
Application number
MA043251A
Other languages
English (en)
Other versions
MA43251B1 (fr
Inventor
Olivier Corminboeuf
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Davide Pozzi
Sylvia Richard-Bildstein
Thierry Sifferlen
Peters Lorenza Wyder
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA43251A publication Critical patent/MA43251A/fr
Publication of MA43251B1 publication Critical patent/MA43251B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
MA43251A 2015-11-20 2016-11-17 Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 MA43251B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (fr) 2015-11-20 2016-11-17 Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2

Publications (2)

Publication Number Publication Date
MA43251A true MA43251A (fr) 2021-04-28
MA43251B1 MA43251B1 (fr) 2021-11-30

Family

ID=57326428

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055046A MA55046A (fr) 2015-11-20 2016-11-17 Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA43251A MA43251B1 (fr) 2015-11-20 2016-11-17 Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055046A MA55046A (fr) 2015-11-20 2016-11-17 Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2

Country Status (33)

Country Link
US (2) US11241431B2 (fr)
EP (2) EP3928836A1 (fr)
JP (2) JP2018534328A (fr)
KR (1) KR102352022B1 (fr)
CN (1) CN108349949B (fr)
AU (1) AU2016358242B2 (fr)
BR (1) BR112018010291B1 (fr)
CA (1) CA3002610C (fr)
CL (1) CL2018001325A1 (fr)
CO (1) CO2018005715A2 (fr)
CR (1) CR20180323A (fr)
CY (1) CY1124913T1 (fr)
DK (1) DK3377483T3 (fr)
EA (1) EA037953B1 (fr)
ES (1) ES2897954T3 (fr)
HR (1) HRP20211678T1 (fr)
HU (1) HUE056679T2 (fr)
IL (1) IL259424B (fr)
LT (1) LT3377483T (fr)
MA (2) MA55046A (fr)
MX (1) MX2018005268A (fr)
MY (1) MY195888A (fr)
PE (1) PE20181304A1 (fr)
PH (1) PH12018501077B1 (fr)
PL (1) PL3377483T3 (fr)
PT (1) PT3377483T (fr)
RS (1) RS62598B1 (fr)
SA (1) SA518391588B1 (fr)
SG (1) SG11201803627XA (fr)
SI (1) SI3377483T1 (fr)
TW (2) TWI719078B (fr)
UA (1) UA123441C2 (fr)
WO (1) WO2017085198A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
PL3625222T3 (pl) 2017-05-18 2021-12-27 Idorsia Pharmaceuticals Ltd Pochodne fenylu jako modulatory receptora pge2
CN110612299A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的嘧啶衍生物
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3735419A4 (fr) 2018-01-05 2021-09-15 Icahn School of Medicine at Mount Sinai Procédé d'augmentation de la prolifération de cellules bêta pancréatiques, procédé de traitement et composition
CA3093340A1 (fr) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et procedes d'utilisation
CN113543783A (zh) * 2018-12-31 2021-10-22 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
EP3693359A1 (fr) * 2019-02-08 2020-08-12 Medibiofarma, S.L. Nouveaux dérivés de n-benzyl-2-phénoxybenzamide en tant que modulateurs des récepteurs de la prostaglandine e2 (pge2)
WO2021060281A1 (fr) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 Antagoniste double des récepteurs ep2/ep4 de la prostaglandine e2
EP4245301A1 (fr) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Traitement du cancer par utilisation combinée d'un antagoniste d'ep4 et d'un inhibiteur de point de contrôle immunitaire

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
CA2402099C (fr) 2000-03-24 2011-04-26 Pharmagene Laboratories Ltd. Methodes pour le traitement des troubles primaires causes par les maux de tete au moyen d'antagonistes du recepteur ep4, et dosages des agents dudit traitement
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
WO2003087061A1 (fr) 2002-04-12 2003-10-23 Pfizer Japan Inc. Composes de pyrazole en tant qu'agents anti-inflammatoires et analgesiques
BR0309305A (pt) 2002-04-12 2005-02-15 Pfizer Compostos de imidazol como agentes antiinflamatórios e analgésicos
CN1662551A (zh) 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
ES2308139T3 (es) 2003-01-29 2008-12-01 Asterand Uk Limited Antagonista de receptos ep4.
WO2005019218A1 (fr) 2003-08-26 2005-03-03 Teijin Pharma Limited Derive de pyrrolopyrimidinethione
OA13247A (en) 2003-09-03 2007-01-31 Pfizer Phenyl or pyridyl amide coumpounds as prostaglandin E2 antagonists.
EP1678147B1 (fr) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005080367A1 (fr) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Agonistes des recepteurs ep2
WO2005105733A1 (fr) 2004-05-04 2005-11-10 Pfizer Japan Inc. Composes aryl- ou heteroarylamides ortho-substitues
KR20070006891A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
JP5289046B2 (ja) 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Ｅｐ４アンタゴニストとしてのキノリン誘導体
WO2006128129A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Traitement anticancereux
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007121578A1 (fr) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Dérivés d'indolamide comme antagonistes du récepteur ep4
WO2007143825A1 (fr) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Dérivés amide de l'indoline en tant que ligands du récepteur ep4
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
AR061974A1 (es) 2006-07-14 2008-08-10 Novartis Ag Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
AU2007283404B2 (en) 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
WO2008039882A1 (fr) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
US8158671B2 (en) 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
CA2681146A1 (fr) 2007-03-26 2008-10-02 Merck Frosst Canada Ltd. Derives de naphtalene et quinoleine sulfonyluree comme antagonistes du recepteur ep4
CN101641325A (zh) 2007-03-26 2010-02-03 安斯泰来制药株式会社 鸟氨酸衍生物
EP2014657A1 (fr) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine en tant que modulateurs du récepteur EP2
WO2009005076A1 (fr) 2007-07-03 2009-01-08 Astellas Pharma Inc. Composé amide
EP2212297B1 (fr) 2007-10-12 2011-05-25 Ingenium Pharmaceuticals GmbH Inhibiteurs de protéine kinases
CA2714743C (fr) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines et triazines en tant que modulateurs d'amide d'acide gras hydrolase
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
WO2010019796A1 (fr) 2008-08-14 2010-02-18 Chemietek, Llc Dérivés d’amides hétérocycliques en tant qu’antagonistes du récepteur ep4
GB2474813B (en) 2008-09-19 2014-05-28 Biotechnology Res Corp Ltd Triterpenoid compounds and methods of use thereof
WO2010034110A1 (fr) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Dérivés de bêta-carboline sulfonylurée en tant qu’antagonistes du récepteur d’ep4
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US20110124667A1 (en) 2009-11-23 2011-05-26 Philip Manton Brown Methods for the treatment of irritable bowel syndrome
CA2798578C (fr) 2010-05-21 2015-12-29 Chemilia Ab Nouveaux derives de pyrimidine
RU2606510C2 (ru) 2010-09-21 2017-01-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция
WO2012043634A1 (fr) 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 Anticorps dirigé contre le récepteur ep4 de la prostaglandine e2 humain
US20130324530A1 (en) 2010-11-17 2013-12-05 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012066065A1 (fr) 2010-11-17 2012-05-24 Novartis Ag Composés phényl-hétéroaryl amine et leurs utilisations
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
WO2012103071A2 (fr) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Composés et compositions
CA2830129C (fr) 2011-03-24 2016-07-19 Chemilia Ab Nouveaux derives de pyrimidine
WO2012149528A1 (fr) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
JP5813223B2 (ja) 2011-07-04 2015-11-17 ロッタファーム バイオテック エス アール エル Ｅｐ４レセプターアンタゴニストとしての環状アミン誘導体
EP2554662A1 (fr) 2011-08-05 2013-02-06 M Maria Pia Cosma Procédés pour le traitement de maladies rétiniennes dégénératives
WO2013090552A1 (fr) 2011-12-13 2013-06-20 Yale University Compositions et procédés pour la réduction de l'épuisement de ctl
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
CA2888338C (fr) 2012-11-27 2021-07-20 Thomas Helledays Stiftelse For Medicinsk Forskning Inhibiteurs mth1 pour le traitement du cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (fr) 2013-02-07 2014-08-13 Almirall, S.A. Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
ES2669977T3 (es) 2013-06-12 2018-05-29 Kaken Pharmaceutical Co., Ltd. Derivado de 4-alquinilimidazol y medicamento que lo comprende como ingrediente activo
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PT3363790T (pt) 2013-09-06 2020-05-06 Aurigene Discovery Tech Ltd Derivados 1,2,4-oxadiazoles como imunomoduladores
WO2015044900A1 (fr) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Composés immunomodulateurs thérapeutiques
DK3057953T3 (en) 2013-10-17 2018-11-19 Vertex Pharma CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS
CN105636958B (zh) 2013-10-17 2018-01-05 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
EP3083562B1 (fr) 2013-12-17 2017-09-27 Eli Lilly & Company Dérivés d'amine cyclique de phénoxyéthyle et leur activité en tant que modulateurs du récepteur ep4
EA028675B1 (ru) 2013-12-17 2017-12-29 Эли Лилли Энд Компани Соединения диметилбензойной кислоты
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
EP3137074B1 (fr) 2014-04-29 2020-08-05 Emory University Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associées
AU2015264102C1 (en) 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
EP3151833A4 (fr) 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Inhibiteurs de mth1 destinés au traitement des états inflammatoires et auto-immuns
WO2016021742A1 (fr) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4
TWI739666B (zh) 2015-01-09 2021-09-11 日商小野藥品工業股份有限公司 醫藥組成物
DK3325490T3 (da) 2015-07-23 2020-02-03 Takeda Pharmaceuticals Co 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister
JP6860559B2 (ja) 2015-10-16 2021-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｅｐ４アンタゴニスト
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018013840A1 (fr) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
ES2929309T3 (es) 2017-05-18 2022-11-28 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2
ES2894124T3 (es) 2017-05-18 2022-02-11 Idorsia Pharmaceuticals Ltd Derivados de indol N-sustituidos
AR111874A1 (es) 2017-05-18 2019-08-28 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
CN110612299A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的嘧啶衍生物
PL3625222T3 (pl) 2017-05-18 2021-12-27 Idorsia Pharmaceuticals Ltd Pochodne fenylu jako modulatory receptora pge2

Also Published As

Publication number Publication date
AU2016358242B2 (en) 2021-03-11
CN108349949A (zh) 2018-07-31
JP2018534328A (ja) 2018-11-22
CN108349949B (zh) 2020-11-17
IL259424A (en) 2018-07-31
KR20180081810A (ko) 2018-07-17
MY195888A (en) 2023-02-27
MA55046A (fr) 2021-12-29
PT3377483T (pt) 2021-11-22
CR20180323A (es) 2018-08-06
RS62598B1 (sr) 2021-12-31
CY1124913T1 (el) 2023-01-05
SG11201803627XA (en) 2018-06-28
HRP20211678T1 (hr) 2022-03-04
SI3377483T1 (sl) 2022-01-31
CA3002610C (fr) 2022-03-15
MA43251B1 (fr) 2021-11-30
PL3377483T3 (pl) 2022-01-31
CO2018005715A2 (es) 2018-07-10
BR112018010291B1 (pt) 2023-12-26
PH12018501077A1 (en) 2019-01-28
TWI719078B (zh) 2021-02-21
EP3377483A1 (fr) 2018-09-26
CL2018001325A1 (es) 2018-08-10
IL259424B (en) 2020-11-30
US20200289507A1 (en) 2020-09-17
PE20181304A1 (es) 2018-08-09
WO2017085198A1 (fr) 2017-05-26
AU2016358242A1 (en) 2018-07-05
EP3928836A1 (fr) 2021-12-29
DK3377483T3 (da) 2021-12-06
TW202120497A (zh) 2021-06-01
BR112018010291A2 (pt) 2018-11-06
MX2018005268A (es) 2018-11-29
HUE056679T2 (hu) 2022-02-28
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
EA201891179A1 (ru) 2018-11-30
PH12018501077B1 (en) 2019-01-28
TW201726661A (zh) 2017-08-01
US20220175775A1 (en) 2022-06-09
ES2897954T3 (es) 2022-03-03
JP7228618B2 (ja) 2023-02-24
EP3377483B1 (fr) 2021-09-01
EP3377483B9 (fr) 2022-08-03
CA3002610A1 (fr) 2017-05-26
EA037953B1 (ru) 2021-06-11
SA518391588B1 (ar) 2021-03-17
KR102352022B1 (ko) 2022-01-14
US11241431B2 (en) 2022-02-08
JP2021107417A (ja) 2021-07-29
TWI754397B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MA49127A (fr) Dérivés d'indole n-substitués
PT3353167T (pt) Moduladores da indolamina 2,3-dioxigenase
HUE056080T2 (hu) Fenilszármazékok mint PGE2 receptor modulátorok
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
IL270620A (en) Pyrimidine history as PGE2 receptor modulators
MA42654A (fr) Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
DK3022174T3 (da) Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
IL252252A0 (en) Transducible bridged urea analogs as sirtuin modulators
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3411332T3 (da) Fremgangsmåde til direkte syntese af jernholdig aei-zeolitkatalysator
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
MA51285A (fr) Dérivés d'azaindole comme inhibiteurs de rho-kinase
DK3309150T3 (da) (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propansyre som histamin-h3-receptormodulatorer til behandlingen af kognitive lidelser
DK3615534T3 (da) Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet
MA43922A (fr) Dã‰rivã‰s d'indane utilisã‰s comme modulateurs de mglur7
IL273237A (en) Novel heterocyclic compounds as MGLUR7 modulators
ES2747993T8 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam